rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
This study is testing if repetitive transcranial magnetic stimulation (rTMS), a device that uses magnetic currents to stimulate specific brain areas, can improve treatment for adults with moderate to severe cocaine use disorder. You might be eligible if you are 22-65 years old, have used cocaine frequently, and are seeking treatment. The study aims to see if rTMS is safe, how it affects the brain, and if it helps people achieve abstinence from cocaine when combined with cognitive-behavioral therapy (CBT). Researchers will measure how many participants complete the rTMS sessions, if there are any side effects, and how brain activity changes.
- Study design
- This is an interventional study planning to enroll 30 participants. It compares active rTMS to a sham (placebo) rTMS, both given before cognitive-behavioral therapy.
- What's involved
- You would have two brain MRI scans, receive 15 daily rTMS (or sham) treatments over 3 weeks, and then attend 12 weeks of once-weekly cognitive-behavioral therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main study outcomes are measured at 3 weeks after starting rTMS treatments.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
At a glance
Conditions
NCT05974202
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS)
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- John Mariani, MD · PRINCIPAL_INVESTIGATOR · New York State Psychiatric Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of participants receiving at least 15 out of 20 rTMS sessions1 week
Feasibility will be measured as the total percentage of participants who receive the defined number of rTMS sessions
- Number of participants experiencing an rTMS-emergent serious adverse event1 week
Safety of rTMS will be measured by the absolute number of serious adverse events that occur in the active rTMS arm
- Number of participants with 15% decrease in RSFC (resting state functional connectivity) between the DLPFC (dorsolateral prefrontal cortex) and anterior cingulate.1 week
Neural mechanism will be evaluated by comparing the active and sham rTMS groups during the fMRI task by comparing baseline fMRI and post-rTMS fMRI measures
- Percentage of participants who achieve 3 weeks of abstinence during the final 12 weeks of the trial12 weeks
Efficacy regarding cocaine use outcomes will be evaluated by comparing the active and sham rTMS groups during the final 12 weeks of the trial while the participants are receiving cognitive behavioral therapy. 3 consecutive weeks of abstinence, as defined by no self-reported cocaine use using the timeline follow-back method and confirmed by qualitative urine benzoylecgonine screening